Clinical Trial

Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a single-arm, open label, non-randomized, phase 2 trial of zanubrutinib in patients with diffuse large B-cell lymphoma (DLBCL) who have an MYD88 L265P mutation, a CD79B mutation, a NOTCH1 truncation, or who are CD5+ by immunohistochemistry (IHC).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-25; most recent amendment 2026-01-21.
Status change: Not Yet Recruiting → Recruiting 2025-05-27
Trial Details
NCT Number NCT06846463
Lead Sponsor Virginia Commonwealth University
Conditions Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
Enrollment 21 participants
Start Date 2025-05-27
Primary Completion 2029-07-31 (estimated)
Study Completion 2032-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-23